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Heparin  cofactor I1 (HC) is a plasma  serine  protein- 
ase  inhibitor  (serpin)  that  inhibits  the  coagulant  pro- 
teinase a-thrombin. We have recently demonstrated 
that proteolysis of HC by catalytic  amounts of poly- 
morphonuclear  leukocyte  proteinases  (elastase or  ca- 
thepsin G) generates  leukocyte  chemotaxins  (Hoffman, 
M., Pratt, C. W., Brown, R. L., and Church, F. C. 
(1989) Blood 73, 1682-1685). One of four peptides 
produced  when HC is degraded by neutrophil elastase 
has chemotactic activity  for  both monocytes and neu- 
trophils  with  maximal  migration  comparable  to  for- 
mytMet-Leu-Phe,  the “gold standard”  bacterially de- 
rived chemotaxin. The amino-terminal  sequence of this 
HC peptide is Asp-Phe-His-Lys-Glu-Asn-Thr-Val-. .  
and  the peptide  corresponds  to Asp-39 to Ile-66 of HC. 
A variety of synthetic  peptides  derived  from  this se- 
quence  were  evaluated  for  leukocyte  migration  activ- 
ity,  and a dodecapeptide from  Asp-49  to  Tyr-60 (Asp- 
Trp-Ile-Pro-Glu-Gly-Glu-Glu-Asp-Asp-Asp-Tyr) was 
identified as the  active site for  leukocyte  chemotactic 
action. The  12-mer  synthetic  peptide possesses signif- 
icant neutrophil chemotactic action at 1 nM (60% of 
the maximal activity of formyl-Met-Leu-Phe),  while a 
peptide  with the  reverse  sequence  has  essentially no 
chemotactic  activity.  Cross-desensitization  experi- 
ments  also  show that  pretreatment of neutrophils  with 
a 19-mer peptide (Asn-48 to Ile-66) greatly reduces 
subsequent  chemotaxis to HC-neutrophil  elastase  pro- 
teolysis reaction products. When injected intraperito- 
neally  in mice, the HC-neutrophil  elastase  digest  elicits 
neutrophil  migration. 
Our  results  demonstrate  that not  only  does HC func- 
tion as a thrombin  inhibitor,  but  that  limited  proteol- 
ysis of  HC near  the  amino  terminus yields  biologically 
active peptide(s) which might participate in inflam- 
mation  and  in wound  healing and tissue  repair  proc- 
esses. 
Serpins are  a protein superfamily of which many members 
possess potent activity as serine proteinase inhibitors (1, 2). 
Interestingly, a number of serpins  are  not proteinase inhibi- 
tors, including angiotensinogen and thyroxine- and cortisol- 
binding globulins found in  human plasma, ovalbumin from 
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chicken egg white, and endosperm protein Z from barley (1- 
3). Two plasma serpins, heparin cofactor I1 (HC)’  and  anti- 
thrombin (AT), inhibit the blood coagulation proteinase a- 
thrombin in a reaction that is dramatically accelerated by 
heparin and other glycosaminoglycans/proteoglycans (4-8). 
Heparan sulfate proteoglycans localized to vessel  walls  may 
be the primary site of intravascular proteinase inhibition 
mediated by AT, while basement membrane/extracellular ma- 
trix  dermatan sulfate proteoglycans might be important for 
HC-mediated thrombin inhibition entruuascularly (6-10). 
Human polymorphonuclear leukocytes (neutrophils) and 
mononuclear phagocytes (monocytes) are important cellular 
components of tissue injury, infection, establishment of acute/ 
chronic inflammation, and wound healing (11,12). Proteolytic 
enzymes and oxidants  are released during activation of neu- 
trophils (11, 12). Limited cleavage of HC by either purified 
neutrophil elastase or cathepsin G or live activated neutro- 
phils releases peptides with discrete biological activity for 
leukocytes (13-16). Neutrophil proteinases might generate 
biologically active peptides from HC without affecting anti- 
thrombin inhibitory action (16). A potential physiological  role 
for HC unrelated to proteinase inhibition may depend on the 
generation of peptides that modulate leukocyte functions. 
We are interested in understanding the functional and 
structural roles of HC compared to AT and other serpins. 
The carboxyl termini of most serpins  are homologous and  are 
the portions of the molecules  involved in proteinase inhibition 
(1). However, the amino terminus of HC has little homology 
to other serpins, including AT (7, 17). Therefore, we hypoth- 
esized that HC may be related in function to the serpin 
homologue angiotensinogen, whose amino terminus generates 
bioactive peptides following limited proteolysis by renin and 
neutrophil proteinases (18, 19). 
We report here that limited neutrophil elastase proteolysis 
of HC produces a peptide derived from the amino-terminal 
region (corresponding to Asp-39 to Ile-66) with chemoattrac- 
tant action for both neutrophils and monocytes. We also 
found that a dodecapeptide from Asp-49 to Tyr-60 of HC  may 
contain the minimal active site for leukocyte migration activ- 
ity. Additionally, we found that the products of an HC- 
neutrophil  elastase digest stimulate neutrophil migration in 
vivo in  mice.  Collectively, our data  further implicate a role  for 
HC-neutrophil proteinase products in local inflammatory re- 
sponses. A preliminary report has appeared in abstract form 
(20). 
The abbreviations used are: HC, heparin cofactor 11; AT, anti- 
thrombin; fMLP, N-formyl-Met-Leu-Phe; hpf, high power fields; 
HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid; HPLC, 
high performance liquid chromatography;  FPLC,  fast  protein liquid 
chromatography;  DMEM, Dulbecco’s modified Eagle  medium; al-PI, 
cq-proteinase  inhibitor. 
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EXPERIMENTAL  PROCEDURES 
Materials-HC and AT were purified from human plasma as 
described (17).  Human  polymorphonuclear leukocyte elastase purified 
from  sputum was obtained  from  Elastin  Products (Pacific, MO)  and 
stored  in 200 mM sodium acetate a t   pH 5.0 at -20 "C. Phenylmeth- 
ylsulfonyl  fluoride and  fMLP were from Sigma. All HC/AT proteol- 
ysis  and  HC  synthetic  peptide  experiments were performed  in a  buffer 
that  contained 20 mM HEPES, 150 mM NaCl, 0.1% (w/v)  polyeth- 
ylene glycol (M, = 8000) a t   pH 7.4. 
Serpin-Neutrophil Elastase Reactions and HPLC-A mixture of 
HC  and  neutrophil  elastase  (2 p~ HC, 20 nM proteinase) was kept at 
room temperature for 40 min at pH 7.4 in the HEPES buffer. 
Phenylmethylsulfonyl fluoride (1 mM) was added  to  terminate  pro- 
teolysis. The digested sample was  analyzed by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis  and,  as visualized, all of the  native 
HC (Mr - 66,000) was converted  to a degradation  product previously 
termed "band 111" (Mr - 48,000; Ref. 16). The HC-neutrophil  elastase 
digest (-100 pg of HC) was chromatographed  on a Phenomenex  W- 
Porex  C-18 column (4.6-mm inner  diameter X 250 mm, with  5-pm 
particles)  with  the column equilibrated  in 0.1% trifluoroacetic acid, 
and a gradient was developed with  2-propanol to  22% in  57  min  and 
then to 60% in 34 min a t  a flow rate of 1 ml/min as described 
previously (21). The  amino  acid sequence of peak 2  (see Figs. 1 and 
2) was determined  on  an Applied Biosystems 470A gas-phase  sequen- 
ator  with  an  on-line  Waters  HPLC. 
Reaction of AT and prothrombin with neutrophil elastase and 
cathepsin G  was performed  using  the  conditions for HC-neutrophil 
proteinase  mixtures  as  detailed previously (13). 
Cell Isolation and Chemotaxis Assay-Monocytes and  neutrophils 
were purified on Ficoll-Hypaque density gradients (Mono-Poly re- 
solving  medium, Flow Laboratories)  from  the blood of healthy vol- 
unteers  as described  previously (13, 14). The purity of the  resulting 
cell preparations was determined by performing  differential  counts 
of Wright's-stained  cytospin  preparations. The neutrophil  prepara- 
tions were routinely 95-99% pure while the  mononuclear  preparations 
routinely  contained fewer than 5% neutrophils  and  eosinophils  and 
about. 40-50% monocytes, with the remaining cells being lympho- 
cytes. 
Chemotaxis was measured in modified Boyden chambers as de- 
tailed previously  (13).  Leukocytes  were suspended at 1.5 X lo6 cells/ 
ml  in Dulbecco's modified Eagle  medium  (DMEM,  GIBCO)  supple- 
mented with 1 mg/ml dextrose, and containing 10% calf serum 
(Sterile  Systems,  Inc.). All buffers, media, and  sera used during  the 
isolation of cells and performance of assays contained <1 ng/ml 
endotoxin. To  the  top well  of each Boyden chamber was added 0.25 
ml of the leukocyte suspension. The  chemoattractant  solution  to be 
tested, or medium alone, was simultaneously added to the bottom 
compartment.  The  compartments of the Boyden chambers were sep- 
arated by a polycarbonate  filter  with 5-pm pores  (Nuclepore,  Inc.). 
The chambers were incubated for 1 h (neutrophils) or 2  h (monocytes) 
at 37 "C in a  humidified atmosphere  containing 5% CO,. The filters 
were fixed in 5% formalin,  stained  with  Wright's  stain,  mounted  in 
immersion oil under coverslips, and  the  number of leukocytes  which 
had migrated across  the  filter was counted  in 10-20 high power fields 
(hpf)  per  filter a t  X 1000 final magnification. The average number of 
leukocytes migrating  in  control  chambers (lower compartment  con- 
tained medium only) was subtracted as background from the  number 
migrating  in  test  chambers,  to yield the  net  number of leukocytes 
migrating per oil field. Positive controls assessing chemotaxis to 
fMLP  to lo-' M) were conducted in parallel  with  the  experi- 
mental groups. Chemotaxis  to a test  substance was expressed  as a 
percentage of the  maximal  chemotaxis  to  fMLP  in  the  same xperi- 
ment. Migration to  each  concentration of each  potential  chemotaxin 
was tested a minimum of three times. 
Peptide Synthesis-Peptides  were  assembled  using  a  Milligen Pep- 
synthesizer  (with Fmoc (N-(9-fluorenyl)methoxycarbonyl)-amino 
acid chemistry following the guidelines  provided  by the  manufacturer) 
according to  the  reported  cDNA sequence  for HC (7). Purity of the 
peptides was  analyzed by reverse-phase HPLC,  and  amino acid analy- 
sis  results were consistent  with  the  theoretical yield. 
The a- and c-amino groups of the 22-mer synthetic  HC  peptide 
were modified with acetic anhydride  (22). The modified peptide was 
separated from other  reagents using Sephadex G-15 equilibrated  in 
100 mM ammonium  bicarbonate. The  extent of amino group  modifi- 
cation was determined  spectrophotometrically  (23). 
Electrophoresis-Sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis was carried  out a t  25 "C using 10% polyacrylamide gels 
as described (24). 
Migration Activity for Mouse Neutrophils  in Viuo-CSH/HeJ mice 
(8 weeks old) were injected intraperitoneally  through a 0.2-pm filter, 
with 1 ml of either  DMEM  alone  (with  10%  neonatal bovine serum), 
or  with 1 ml of a 0.1 p~ solution of HC-neutrophil elastase digest 
(13)  or  HC  alone  in  DMEM  with  neonatal bovine serum. One hour 
after injection, peritoneal cells were recovered by lavage with  DMEM 
with 10% neonatal bovine serum  and  10  units/ml  heparin.  The cells 
were sedimented,  counted  in  the  Coulter  counter,  and  cytopsins made
of the  harvested cells and  stained  with  Wright's  stain. Differential 
counts of the harvested cells were done under an oil immersion 
microscope. In  vivo migration  experiments were each performed three 
times. 
RESULTS 
Isolation of a Unique Chemotactic Peptide following Limited 
Neutrophil Elastase Proteolysis of HC-The peptides pro- 
duced  when HC  is degraded by catalytic  amounts of neutrophil 
elastase were purified by reverse-phase  HPLC  and  tested for 
chemotactic  activity (Fig. 1). Of the four peaks  separated by 
HPLC, only peak 2 was found  to  have  significant  chemotactic 
activity for both  neutrophils  and monocytes. Primary  struc- 
tural  analysis of this  peptide revealed  a  sequence of Asp-Phe- 
His-Lys-Glu-Asn-Thr-Val-. . . . Amino acid analysis of this 
peptide  matches  the sequence in  HC from Asp-39 to Ile-66 
(data  not included). I t  is  not known whether  the  chemotactic 
activity  generated from HC by cathepsin G is localized to  this 
same region; however, cathepsin G also  hydrolyzes HC at the 
Ile6'j-Phe bond (16). These results indicate that neutrophil 
elastase cleaves HC  into several fragments,  but  there  is only 
one  distinct  peptide  generated from the  amino  terminus  that 
possesses  leukocyte chemotactic  action. 
Synthetic  HC  Peptides Mimic the Chemotactic Action of the 
HC-Neutrophil  Elastase Digest-To determine  whether  part 
or  all of the sequence contained  within Asp-39 to Ile-66 of 
HC  is required for chemotactic  activity, we prepared  synthetic 
peptides  spanning  this region (sequences are shown in Fig. 2) 
and measured their  chemotactic  potential (shown in Fig. 3 for 
neutrophils): from  Asp-39 to  Asn-48  (10-mer  peptide), Asn- 
48 to  Ile-66 (19-mer peptide), Asp-39 to Tyr-60 (22-mer 
peptide), and the entire Asp-39 to Ile-66 sequence (28-mer 
peptide). As found for the  HPLC-purified  HC  fragment com- 
posed of residues 39-66, the  synthetic 28-mer  peptide was an 
effective chemotaxin for neutrophils (60% of fMLP  at  1 X 
lo-" M 28-mer  peptide; data  not  shown).  The 22-mer  peptide 
had  chemotactic  activity  (at  nanomolar  concentrations) for 
both monocytes (40% of fMLP) and neutrophils (38% of 
fMLP), as did the 19-mer peptide for monocytes (30% of 
fMLP)  and  neutrophils (27% of fMLP),  but  the  10-mer  pep- 
tide was inactive  (6% of fMLP) (Fig. 3). Interestingly, acety- 
lation of the a- and  t-amino groups of the 22-mer  peptide did 
not  diminish leukocyte chemotactic  activity compared to  the 
sham-modified 22-mer peptide  (data  not  shown). Leukocyte 
chemotaxis  to a synthetic  peptide from another region of HC 
from Phe-183 to Arg-200 (18-mer peptide) gave negative 
results (Fig. 3). These  results show that  the  19-mer  and 22- 
mer  peptides mimic the bioactivity of the Asp-39 to Ile-66 HC 
peptide, and we conclude that the dodecapeptide sequence 
from Asp-49 to Tyr-60 (Asp-Trp-Ile-Pro-Glu-Gly-Glu-Glu- 
Asp-Asp-Asp-Tyr) may constitute  the  minimal active region. 
To  further  assess  the ability of the region contained  within 
Asp-49 to  Tyr-60 of HC  to elicit leukocyte chemotaxis, we 
assembled the  12-mer  peptide based on  its correct  sequence 
and a synthetic peptide based on a reverse sequence (r-12- 
mer;  sequence  shown in Fig. 2). Elution of the  12-mer  and  r- 
12-mer  peptides was identical when  analyzed by FLPC  ion- 
exchange chromatography (Fig. 4). However, the  12-mer  pep- 
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FIG. 1. Neutrophil elastase prote- 
olysis of HC, peptide purification by 
HPLC, and leukocyte chemotactic 
activity of peptides. Top, the HC-neu- 
trophil elastase limitedproteolysis digest 
was prepared and analyzed by reverse- 
phase HPLC as described under "Exper- 
imental Procedures." Shown here is the 
210-nm absorbance profile of the digest, 
where absorbance full scale is 0.25. Each 
peak was collected and then lyophilized 
to remove any residual solvent. Bottom, 
redissolved peptides (in a total volume 
of 1 ml in the  HEPES buffer) were meas- 
ured for their leukocyte chemotactic ac- 
tivity as described under "Experimental 
Procedures": peak 1 (H), peak 2 (H), and 
peak 3 a). The results are expressed at 
a 1:100 and 1:lOOO dilution of the redis- 
solved peaks (peaks 1-3) as  the  net num- 
ber of either neutrophils or monocytes 
migrating per x 1000 field as a  percent- 
age of the maximal migration of fh4LP 
(29.5 neutrophils/hpf; 13.4 monocytes/ 
hpf). Each point represents the mean of 
duplicate determinations, and the bars 
represent the range of counts. Peak 4 
was not chemotactic for neutrophils and 
was not  further evaluated (data not 
shown). Control solutions (following ly- 
ophilization and redissolution) at the 
same trifluoroacetic acid/2-propanol 
mixture at which each peak eluted from 
the HPLC column were also tested and 
showed no chemotactic activity ( 4 0 %  
of fMLP). 
A Q 
10-mer  Asp % - A m  48 
19-mer A m  48-lle 66 
22-mer Asp 39-Tyr 60 
12-mer Asp 49-Tyr 60 
FIG. 2. Amino acid sequences of HC peptides. 
tide possessed significant neutrophil chemotactic action (60% 
of fMLP at 1 nM 12-mer peptide) while the r-12-mer peptide 
was essentially inactive as  a chemotaxin (<lo% of fMLP at 
lo-" to M r-12-mer peptide) (Fig. 4). These results 
suggest that  the leukocyte chemotactic action of HC peptides 
(containing Asp-49 to Tyr-60) is dependent upon a unique 
structural  determinant derived from its amino acid sequence 
and this activity is not dependent upon interactions based 
solely  on charge. 











phils to  further chemotactic action was examined. Exposure 
of neutrophils to fMLP down-regulates the fMLP receptor 
and desensitizes the cells to subsequent exposure to fMLP 
(25). Neutrophils preincubated with the 19-mer peptide did 
not migrate to a gradient of the HC-neutrophil elastase digest 
on subsequent testing  (Table I). We also found that  the 19- 
mer peptide and fMLP did not cross-desensitize, indicating 
that  the HC-derived chemotaxin does not  bind to  the fMLP 
receptor (Table I). These results further indicate that the 
specific chemotactic activity generated from an HC-neutro- 
phi1 elastase digest is primarily contained within the Asp-39 
to Ile-66 peptide. 
Limited Proteolysis of Antithrombin and Prothrombin with 
Neutrophil Proteinases-Unlike HC, no significant neutrophil 
chemotactic activity was generated by the reaction of AT with 
either neutrophil elastase or cathepsin G (Table 11). Electro- 
phoretic analysis of the AT/neutrophil elastase reaction prod- 
ucts verified previous observations of a cleavage site about 5 
kDa from the carboxyl terminus in AT with no apparent 
amino-terminal degradation (26, 27). While AT is rapidly 
inactivated by exposure to neutrophil proteinases, HC is 
initially degraded at the amino terminus to a species that 
retains  thrombin inhibitory activity, further suggesting dif- 
ferent functional roles for the amino termini of the two serpins 
(16,  26-28). Additionally, limited digestion of prothrombin by 
the neutrophil proteinases resulted in multiple peptides dur- 
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FIG. 3. Neutrophil chemotactic activity of synthetic pep- 
tides derived from the region of Asp-39 to Ile-66 in HC. 
Chemotaxis to dilutions of the reaction mixtures was assayed as 
described under  “Experimental  Procedures” for the  10-mer  peptide 
(O), 19-mer  peptide (A), and  22-mer  peptide (W) from  Asp-39 to Ile- 
66, and  the  18-mer  peptide (A) from  the region of Phe-183  to Arg- 
200. The concentration of chemoattractant  in  the lower wells of the 
Boyden chambers  is  expressed  on  the x-axis as the  logarithm of the 
molar  concentration of each individual synthetic  peptide.  The  results 
are expressed as  the  net  number of neutrophils  migrating  per X 1000 
field as a percentage of the  maximal  migration  to  fMLP (34.9 ? 14.5 
neutrophils/hpf). Each point represents the mean of at  least two 
separate  experiments  performed  in duplicate. 
ing the 5-min incubation (data not included) but without 
generation of any dramatic leukocyte chemotactic activity 
(Table 11). The  absence of formation of leukocyte  bioactive 
peptides from AT  and  prothrombin  (another common plasma 
protein) following neutrophil  proteinase digestion  implies that 
the  generation of leukocyte  bioactive peptides  from  HC may 
be a unique event. 
In   V ivo  Chemotactic  Activity of the  HC-Neutrophil  Elastase 
Digest-The ability of an  HC-neutrophil elastase digest to 
stimulate  neutrophil  migration in vivo was addressed by in- 
jecting mice intraperitoneally,  and  quantifying  neutrophils  in 
the  exudate.  The  HC-neutrophil  elastase digest (at 0.1 PM) 
demonstrated  neutrophil  migration  action in vivo compared 
to  the  same  amount of HC  alone  or  to medium alone  (Table 
111). Control  experiments verified that  isolated mouse neutro- 
phils migrated in a similar  manner  to  human  neutrophils  with 
HC-neutrophil  elastase digests and fh4LP (data  not included). 
These  observations imply that  the proteolysis products of the 
HC-neutrophil elastase digests induce neutrophil migration 
in vivo. 
DISCUSSION 
This  study was undertaken  to  identify  the leukocyte chemo- 
attractant  site  in  HC.  Treatment of purified human  HC  with 
isolated human  neutrophil  elastase,  with  cathepsin G, or with 
live stimulated  neutrophils produces HC  fragments  with  po- 
tent effects on leukocyte function (13-16). Our  results  dem- 
onstrate  that  HC is proteolyzed by neutrophil  elastase  under 
physiological conditions  to release a peptide composed of Asp- 
39 to Ile-66. It is not known whether the sulfated tyrosyl 
residue (29) potentially present in HC and the biologically 
derived peptide  (at residue  60) augments  chemotaxis.  None- 
theless,  synthetic  peptides  based  on  this region in  HC  with 
nonsulfated tyrosyl residues were quite effective leukocyte 
100 
90 
0 1 2 3 4 5 E 7 
Elution Volume < A U >  
1 
1 
A .\ u 
-12 -11 -10 -9 -8 -7 -E 
Log CHC P e p t  i d e l  <M> 
FIG. 4. FPLC and neutrophil chemotaxis of the 12-mer and 
r-12-mer HC synthetic peptides. Top, the  peptides were applied 
to a Mono Q (HR5/5) column at a flow rate of 1 ml/min in 20 mM 
ammonium  acetate,  pH 8.0, at room temperature. After  washing for 
2 min, the 12-mer (solid line) and the r-12-mer (dashed line) were 
eluted  using a linear  gradient from 20 mM to 4 M ammonium  acetate, 
pH 8.0. Shown here is the 280-nm absorbance profile in arbitrary 
units (AU). Bottom, neutrophil chemotactic activity of the 12-mer 
(B) and  r-12-mer (0). The  results  are expressed as the  net  number 
of neutrophils migrating per X 1000 field as a percentage of the 
maximal migration of fMLP (38.8 ? 13.4 neutrophils/hpf). Each 
point represents the mean of a t  least three separate experiments 
performed  in duplicate. 
chemotaxins. A dodecapeptide sequence encoded by Asp-49 
to  Tyr-60 may comprise the  principal  site for  leukocyte  mi- 
gration activity. A reverse  sequence peptide based on Asp-49 
to  Tyr-60  has  no  chemotactic  action. 
The  generation of leukocyte chemotactic  peptides from HC 
following limited neutrophil elastase proteolysis suggests a 
novel function for the  amino  terminus of this  serpin which is 
not  related  to  serine  proteinase  inhibition. A schematic  dia- 
gram illustrating some of the structural features of HC is 
shown in Fig. 5 .  The proteinase reactive site region including 
the reactive site  peptide  bond of L e ~ ~ ~ ~ - S e r ~ ~ ~  is located near 
the carboxyl terminus.  The  putative glycosaminoglycan-bind- 
ing site is situated in a very basic region of the molecule 
centered from  Lys-173 to Phe-195. 
The  EuGene  PIR  protein sequence data  banks were 
searched for human  proteins which might  contain or partially 
resemble the  chemotactic  active  site  in  HC Asp-49 to  Tyr-60 
(Asp-Trp-Ile-Pro-Glu-Gly-Glu-Glu-Asp-Asp-Asp-Tyr). The
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TABLE I 
Neutrophil chemotaxis after preincubation with the 19-mer synthetic 
HC chemotactic peptide 
Neutrophils were incubated with or without fMLP or the 19-mer 
peptide (each at lo-’ M for 10 min) prior to testing chemotaxis to 
fMLP or  the  HC-neutrophil  elastase digest (prepared by reacting the 
components for 5 min as described in Ref. 13). The concentration of 
each chemoattractant in the lower  wells of the Boyden chambers was 
lo-* M. Chemotaxis was performed as described under “Experimental 
Procedures.” The  data show mean values f S.E. (n  = 31. 
Pretreatment 







19-Mer HC synthetic peptide 87 f 20 19 f 7 
100 93 f 22 
26 f 7 96 f 25 
a Results are expressed as  the net number of neutrophils migrating 
as a percentage of the maximal migration to fMLP (47.7 f 9.0 
neutrophils/hpf). 
TABLE I1
Neutrophil chemotaxis  with serpins, prothrombin, proteinases, and 
their digests 
Serpin/prothrombin/proteinase digests were performed as de- 
scribed under “Experimental Procedures” and Ref. 13. The results 
are reported as the maximum percent chemotaxis (at to lo-’ M 
chemotactic agent) relative to fMLP and represent a t  least three 
separate determinations. 
Serpin/protein(ase)/digest Maximum chemotaxis (as % of fMLP) 
Antithrombin (AT) 
AT 0 
AT-cathepsin G 7 
AT-neutrophil elastase 16 
Prothrombin 
Prothrombin 8 
Prothrombin-cathepsin G 8 
Prothrombin-neutrophil elastase 8 
HC 4 
HC-cathepsin G 117 
HC-neutrophil elastase 48 
Cathepsin G 5 
Neutrophil elastase 3 
Data for HC and proteinases are taken from Ref.  13. 
Heparin cofactor I1 (HC)” 
Proteinase” 
TABLE 111 
Migration of mouse neutrophils to HC-neutrophil elastase digest 
in vivo 
The in vivo migration activity in mice  was performed as described 
under “ExDerimental Procedures.” 
Sample % neutrophils a t  60 min“ 
Medium alone 2.3 f 2.3 
HC control 3.7 f 3.8 
HC-neutroDhi1 elastase digest 8.7 f 2.1 
a n = 3; paired t test of percent neutrophils in the various samples 
resulted in a p < 0.005 between the HC-neutrophil elastase digest 
and the medium alone, a p < 0.025 between the HC-neutrophil 
elastase digest and the HC control, and a p > 0.1 for the medium 
alone and the HC control. The total number of peritoneal cells 
recovered from the medium alone, HC control and HC-neutrophil 
elastase digest groups was 0.52 f 0.20 X lo6, 0.65 f 0.35 X lo6, and 
0.94 f 0.16 X lo6, respectively. 
closest sequence matches were high molecular weight kini- 
nogen from Asp-586 to Asp-594 (Asp-Trp-Ile-Pro-Asp-Ile- 
Gln-Thr-Asp) and epidermal growth factor receptor from 
Trp-586 to Glu-591 (Trp-Ile-Pro-Glu-Gly-Glu). The unique 
Bloact ive  Glycosamlnoglycan-  Pro te inase   React lve  
Fragment  blndlng  Domain Slte  Dornnin 
FIG. 5. Structural features of  heparin  cofactor 11. 
bioactive sequence in HC suggests that generation of this 
peptide following neutrophil elastase (or cathepsin  G) limited 
proteolysis could be a novel in vivo function for this serpin. 
We have presented preliminary evidence that HC-neutrophil 
elastase digest products are active in vivo in mice.  Our data 
support the hypothesis described by Saroff and  Pretorius  (30) 
“that specific  biologic functions of some proteins may reside 
in  their unique subsequences with their functions being ex- 
pressed upon degradation of the  parent protein.” 
Henry (31) demonstrated that leukocytes accumulate in 
thrombi i n  vivo. Plow (32) showed that active elastase is 
released from neutrophils during blood coagulation. Kalli- 
krein can also release elastase from neutrophils during throm- 
bus formation (33). Thus, a scenario exists whereby active 
neutrophil  elastase within a  thrombus can proteolyze many 
protein  substrates including HC. The physiological concen- 
tration of HC is 1.2 pM (34). Maximal activity of the HC 
peptides i n  vitro is centered around 1 nM, which suggests that 
only 0.1% of the available HC need be  cleaved by neutrophil 
elastase for generation of physiologically active levels of leu- 
kocyte-modulating peptides i n  uiuo. Janoff (35) noted that 
there are several ways for neutrophil elastase to escape its 
physiological inhibitor,  al-proteinase  inhibitor (al-PI): (i) 
proteinase release in sufficient amounts to overwhelm the 
inhibitor;  (ii) release of proteinase in close proximity to its 
substrates which then “compete” with the inhibitor;  and  (iii) 
proteinase release at sites where inhibitor is inactivated by 
neutrophil oxidizing systems. 
Neutrophil chemotactic activity is generated when al-PI, 
also a serpin, is reacted with neutrophil elastase (36, 37). 
Neutrophil elastase cleaves al-PI at its reactive site  and forms 
a 1:l complex with the inhibitor which lacks proteolytic 
activity. By contrast, neutrophil elastase degrades HC to 
initially yield a molecule  which retains  thrombin inhibitory 
activity (16).  This HC species is then inactivated by further 
proteolysis near the reactive site. The chemotactic activity 
from al-PI resides in the reactive site peptide, which remains 
noncovalently associated with the  al-PI-neutrophil elastase 
complex (36, 37). The reactive site peptide derives from the 
carboxyl terminus of the  al-PI molecule (36, 37). Synthetic 
peptides containing  portions of the  al-PI reactive site peptide 
amino acid sequence also bind to human monocytes and 
hepatoma cells (38). We have previously shown that the 
chemotactic activity produced by proteolysis of HC is biolog- 
ically quite different from that derived from al-PI (13-16): (i) 
al-PI-neutrophil  elastase complexes are strongly chemotactic 
only for neutrophils  (36,37),  but HC proteolysis products are 
chemotactic for both neutrophils and monocytes; (ii) chemo- 
tactic activity of al-PI is  localized to  the reactive site peptide 
near the carboxyl terminus  (36,37) while the HC chemotactic 
activity is juxtaposed to a region near the amino terminus; 
and  (iii)  al-PI-neutrophil  elastase complexes and HC prote- 
olysis products do not bind to  the same receptor on neutro- 
phils, based on data from cross-desensitization experiments. 
These  data presented in the current report extend our pre- 
vious conclusions by demonstrating that  the chemoattractant 
peptides from HC and al-PI are  not only  biologically, but also 
structurally,  distinct. 
Heparin Cofactor II Chemoattractant  Peptides 709 
In summary, our data suggest that evolution has  adapted 
the serpin molecular structure in HC for multiple biologic 
functions: a region for proteinase active site recognition and 
inhibition (7, 8, 17)'; a region similar to  that found in AT for 
interaction with glycosaminoglycans that greatly enhances 
the proteinase inhibitory action (7, 8, 40-42); and a region 
near  the amino terminus which releases bioactive peptides, in 
a manner that is remarkably similar to  its serpin homologue 
angiotensinogen (18,19). Our results raise the possibility that 
HC might link coagulation/anticoagulation and inflamma- 
tion/immune processes. We therefore conclude that HC-de- 
rived bioactive peptides may contribute to leukocyte recruit- 
ment at sites of thrombosis (31, 32), may  modify or influence 
acute  and/or chronic inflammatory responses (11,12),  or may 
participate in wound healing and  tissue repair mechanisms 
(43). 
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